Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jbmr.2429 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synergistic effects of sequential treatment with doxorubicin and zoledronic acid on anticancer effects in estrogen receptor-negative breast cancer cells.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road., Pathumwan, Bangkok, 10330, Thailand.
Zoledronic acid (ZA), a bisphosphonate, is commonly used in breast cancer patients with bone metastases to treat hypercalcemia and osteolysis. Recent studies showed the anti-cancer effects of ZA in breast cancer. This study further explored the synergistic effects of sequential and nonsequential ZA and doxorubicin (DOX) administration on estrogen receptor (ER)-positive and -negative breast cancer cell lines.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to assess how effective a gel with active oxygen is in preventing Medication-Related Osteonecrosis of the Jaw (MRONJ) in a rat model.
- - Twelve rats underwent surgery after receiving a drug (zoledronate) known to cause osteonecrosis and were divided into two groups: one treated with oxygen gel and the other left untreated.
- - Results showed that the untreated group had more severe MRONJ symptoms, suggesting that the gel may help in preventing this condition, although further research is needed due to the pilot nature of the study.
Background: Observational studies using real-world data (RWD) can address gaps in knowledge on deprescribing medications but are subject to methodological issues. Limited data exist on the methods employed to use RWD to measure the effects of deprescribing.
Objective: To describe methodological approaches used in observational studies of deprescribing medications in older adults.
Transient Osteoporosis of Hip as a Part of "Long COVID-19": A Case Series.
J Orthop Case Rep
November 2024
Department of Orthopaedics, P D Hinduja Hospital and Medical Research Centre, Veer Savarkar Marg, Mahim (West), Mumbai, Maharashtra, India.
Introduction: Transient osteoporosis of the hip (TOH) presents with symptoms such as groin pain, discomfort, and the presence of bone edema detected on magnetic resonance imaging (MRI) scans. We have observed an increase in the occurrence of TOH in patients following the COVID-19 pandemic.
Case Report: In this series, we present four cases of TOH that developed after COVID-19 infection.
Zoledronate Sequential Therapy After Denosumab Discontinuation to Prevent Bone Mineral Density Reduction: A Randomized Clinical Trial.
JAMA Netw Open
November 2024
Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Article Synopsis
- - Discontinuing denosumab without another antiresorptive treatment leads to rapid bone loss and higher fracture risks; previous studies on using zoledronate as a follow-up therapy provided mixed results.
- - The study aimed to assess the effect of zoledronate in preventing bone density loss after stopping denosumab, enrolling postmenopausal participants over 50 who had been on denosumab for at least two years.
- - Results from 101 patients showed that those who switched to zoledronate (group ZOL) experienced a significant bone mineral density decrease in the lumbar spine compared to those who continued denosumab (group A) in the first year.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!